Oxytocin in Uniject™ versus misoprostol for prevention of postpartum hemorrhage at the community level: A cluster randomized controlled trial
Lancet Global Health; 2016 Jan; 4(1): e37–44; doi:10.1016/S2214-109X(15)00219-3
Where access to conventional injectable uterotonics to prevent PPH is limited, alternative intervention options using uterotonics could play an important role in reducing the incidence of PPH when given to women after childbirth by less skilled providers. This one-page document summarizes a study comparing the programmatic effectiveness and feasibility of misoprostol and oxytocin in Uniject™ for preventing PPH. While both drugs were found to be safe and efficacious, ease of use, higher acceptability and fewer logistical challenges made misoprostol a more adaptable intervention option in rural Senegal, the setting for the study.